Skip to content
2000
Volume 17, Issue 32
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

The prodrug design is a versatile, powerful method that can be applied to a wide range of parent drug molecules, administration routes, and formulations. Clinically, the majority of prodrugs are used with the aim of enhancing drug permeation by increasing lipophilicity, or by improving aqueous solubility. Prodrug design may improve the bioavailability of parent molecule, and thus can be integrated into the iterative process of lead optimization, rather than employing it as a post-hoc approach. The purpose of this review is to provide an update of advances and progress in the knowledge of current strategic approaches of prodrug design, along with their real-world utility in drug discovery and development. The review covers the type of prodrugs and functional groups that are amenable to prodrug design. Various prodrug approaches for improving oral drug delivery are discussed, with numerous examples of marketed prodrugs, including improved aqueous solubility, improved lipophilicity, transporter-mediated absorption, and prodrug design to achieve site-specific delivery. Tools employed for prodrug screening, and specific challenges in prodrug research and development are also elaborated. This article is intended to encourage discovery scientists to be creative and consider a rationally designed prodrug approach during the lead optimization phase of drug discovery programs, when the structure activity relationship (SAR) for the drug target is incompatible with pharmacokinetic or biopharmaceutical objectives.

Loading

Article metrics loading...

/content/journals/cmc/10.2174/092986710793205426
2010-11-01
2025-01-16
Loading full text...

Full text loading...

/content/journals/cmc/10.2174/092986710793205426
Loading

  • Article Type:
    Research Article
Keyword(s): 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA); Absorption; Acyclovir; Acyloxyalkyl Prodrugs; adefovir dipivoxil; angiotensin-converting enzyme (ACE); antibody-directed enzyme prodrug therapy (ADEPT); antimicrobial prodrugs; antiparasitic; antiproliferative agent; antitubercular; bacampicillin; bambuterol; bioavailability; Bioprecursor; blood-brain barrier; Bopindolol; Caco-2; Capecitabine; Carbamate Prodrugs; Carrier-linked prodrugs; carrier-mediated transport; Chemical delivey System (CDS); colonic mucosa; cyclophosphamide; cytotoxic agents; desglymidodrine; Dipivefrine; distribution, metabolism, and excretion (ADME); Docarpamine; drug targeting; Enalapril; enterocyte; fosphenytoin; Gabapentin; Gancyclovir; gene-directed enzyme prodrug therapy (GDEPT); Glaucoma; Hepatic clearance; hydroxyethylnicotinamide; hypoxia; intestinal epithelium; lipophilicity; Losartan; Lovastatin; Melevodapa; Mestranol; metronidazol; nalbuphine; neoplastic cells; Nitazoxamide; nitroarenes; nitroimidazooxazine; Nitroreductase; nucleoside monophosphonate (NMP); omeprazole action; oseltamivir; Oxidative; oximes; P-glycoprotein; permeability; pharmacokinetic properties; Phosphate Ester Prodrugs; polymorphism; prodrug; protease inhibitors; Quinapril; Schiff Base Prodrugs; Simvastatin; solubility; Spirapril; structure ac-tivity relationship (SAR); Sulfasalazine; Sulindac; sulindac; tenofovir disoproxil; Terfenadine; transporter; transporter-mediated absorption; Tumour Targeting; Viramidine; γ-aminobutyric acid (GABA)
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test